Macpherson Edward Clouston Acquires MIRA Pharmaceuticals Shares

Macpherson Edward Clouston, an insider at MIRA Pharmaceuticals, Inc. (NasdaqCM: MIRA), has acquired 50,000 shares of the company. This transaction took place on June 12, 2026. The shares of MIRA Pharmaceuticals recently traded at $0.93.

Other Institutional Activity in MIRA Pharmaceuticals

Several institutional investors have recently adjusted their holdings in MIRA Pharmaceuticals. Vanguard Capital Management LLC increased its position significantly by adding 693,912 shares, resulting in a total of 693,912 shares valued at about $742,486. Geode Capital Management, LLC also grew its holdings, adding 18,012 shares to end with 290,890 shares worth approximately $311,251. Meanwhile, Suncoast Equity Management reduced its stake by 12,644 shares, leaving it with 90,645 shares valued at around $96,990.

MIRA Pharmaceuticals, Inc. Stock Up 24.2%

Shares of MIRA Pharmaceuticals, trading under the ticker MIRA on NasdaqCM, are currently priced near $0.93. The company, with a market capitalization of about $39.2 million, operates in the healthcare sector, specifically within drug manufacturing. The stock's 52-week range is between $0.90 and $2.45. It has a 50-day moving average of $1.02 and a 200-day moving average of $1.28. MIRA Pharmaceuticals boasts a high current ratio of 82.156, indicating strong liquidity.

Insider Buying and Selling at MIRA Pharmaceuticals, Inc.

In addition to Macpherson Edward Clouston, several other insiders made purchases on June 12, 2026. Matthew Paul Del Giudice, Matthew Pratt Whalen, and Denil Nanji Shekhat each bought 50,000 shares. These purchases were not planned under a Rule 10b5-1 trading plan. Previously, on December 17, 2025, Erez Aminov, the CEO and Chairman, also acquired 3,155,170 shares.

About MIRA Pharmaceuticals

MIRA Pharmaceuticals, Inc., headquartered in Miami, Florida, is a pre-clinical-stage pharmaceutical development company. It focuses on developing treatments for neurologic and neuropsychiatric disorders. The company holds exclusive rights for Ketamir-2, an NMDA receptor modulator, across the U.S., Canada, and Mexico. Additionally, MIRA is developing MIRA-55, a treatment for anxiety and cognitive decline linked to early-stage dementia, and SKNY-1 for obesity and nicotine dependence. Founded in 2020, MIRA Pharmaceuticals is led by CEO Erez Aminov.

Bottom Line

The recent insider purchase by Macpherson Edward Clouston highlights ongoing interest in MIRA Pharmaceuticals. Investors often track insider transactions for potential insights into a company's prospects. However, it's important to note that these filings are retrospective and may not reflect the current position of insiders or the company's future performance.